About Orchestra BioMed Holdings, Inc.
https://orchestrabiomed.comOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
CEO
David P. Hochman
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 23
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RTW INVESTMENTS, LP
Shares:8.31M
Value:$37.05M
PERCEPTIVE ADVISORS LLC
Shares:5.29M
Value:$23.6M
BLACKROCK INC.
Shares:1.86M
Value:$8.32M
Summary
Showing Top 3 of 57
About Orchestra BioMed Holdings, Inc.
https://orchestrabiomed.comOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $861K ▲ | $21.13M ▲ | $-20.83M ▼ | -2.42K% ▼ | $-0.4 ▲ | $-20.23M ▼ |
| Q2-2025 | $836K ▼ | $20.12M ▲ | $-19.36M ▼ | -2.32K% ▼ | $-0.5 ▼ | $-19.25M ▼ |
| Q1-2025 | $868K ▲ | $19.75M ▲ | $-18.75M ▼ | -2.16K% ▲ | $-0.49 ▼ | $-18.67M ▼ |
| Q4-2024 | $253K ▼ | $16.87M ▼ | $-16.16M ▼ | -6.39K% ▼ | $-0.42 ▼ | $-16.59M ▼ |
| Q3-2024 | $987K | $17.26M | $-15.43M | -1.56K% | $-0.41 | $-16.27M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $95.82M ▲ | $104.81M ▲ | $61.07M ▲ | $43.74M ▲ |
| Q2-2025 | $33.92M ▼ | $42.83M ▼ | $42.53M ▲ | $295K ▼ |
| Q1-2025 | $49.88M ▼ | $59.05M ▼ | $42.19M ▼ | $16.86M ▼ |
| Q4-2024 | $66.81M ▼ | $76.17M ▲ | $43.22M ▲ | $32.96M ▼ |
| Q3-2024 | $66.93M | $75.32M | $29.1M | $46.22M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.83M ▼ | $-14.55M ▲ | $-38.58M ▼ | $76.4M ▲ | $23.26M ▲ | $-14.86M ▲ |
| Q2-2025 | $-19.36M ▼ | $-15.53M ▲ | $16.36M ▲ | $-428K ▼ | $401K ▲ | $-15.56M ▲ |
| Q1-2025 | $-18.75M ▼ | $-16.62M ▼ | $13M ▲ | $-296K ▼ | $-3.91M ▼ | $-16.73M ▼ |
| Q4-2024 | $-16.16M ▼ | $-13.54M ▲ | $-3.75M ▼ | $13.95M ▼ | $-3.34M ▼ | $-13.64M ▲ |
| Q3-2024 | $-15.43M | $-13.7M | $557K | $15.04M | $1.89M | $-13.77M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
David P. Hochman
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 23
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RTW INVESTMENTS, LP
Shares:8.31M
Value:$37.05M
PERCEPTIVE ADVISORS LLC
Shares:5.29M
Value:$23.6M
BLACKROCK INC.
Shares:1.86M
Value:$8.32M
Summary
Showing Top 3 of 57